MD FRCPC - Edesa Biotech Company CEO
| EDSA Stock | USD 2.17 0.06 2.84% |
Insider
MD FRCPC is Company CEO of Edesa Biotech
| Age | 53 |
| Address | 100 Spy Court, Markham, ON, Canada, L3R 5H6 |
| Phone | 289 800 9600 |
| Web | https://www.edesabiotech.com |
Edesa Biotech Management Efficiency
The company has return on total asset (ROA) of (0.7152) % which means that it has lost $0.7152 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2929) %, meaning that it created substantial loss on money invested by shareholders. Edesa Biotech's management efficiency ratios could be used to measure how well Edesa Biotech manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.61. In addition to that, Return On Capital Employed is expected to decline to -0.46. At present, Edesa Biotech's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 209.5 K, whereas Total Assets are forecasted to decline to about 8.7 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| David MBA | Seres Therapeutics | 63 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Jeff York | Seres Therapeutics | N/A | |
| BBA CPA | Lumos Pharma | 57 | |
| Bradley JD | Lumos Pharma | 45 | |
| Carl Langren | Lumos Pharma | 69 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Richard Hawkins | Lumos Pharma | 75 | |
| Lori CPA | Lumos Pharma | 40 | |
| James JD | Eliem Therapeutics | 58 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
| Hing Wong | HCW Biologics | 70 | |
Management Performance
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.72 |
Edesa Biotech Leadership Team
Elected by the shareholders, the Edesa Biotech's board of directors comprises two types of representatives: Edesa Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Edesa. The board's role is to monitor Edesa Biotech's management team and ensure that shareholders' interests are well served. Edesa Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Edesa Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| BA CPA, Chief Officer | ||
| Dr MBA, President | ||
| Gary Koppenjan, VP Communications | ||
| MD FRCPC, Company CEO | ||
| Rajan Puri, VP Manufacturing | ||
| BA CA, Chief Officer |
Edesa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Edesa Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.72 | ||||
| Current Valuation | 5.04 M | ||||
| Shares Outstanding | 3.25 M | ||||
| Shares Owned By Insiders | 33.02 % | ||||
| Shares Owned By Institutions | 12.19 % | ||||
| Number Of Shares Shorted | 16.55 K | ||||
| Price To Earning | (3.96) X | ||||
| Price To Book | 2.46 X | ||||
| Price To Sales | 120,478 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.78) | Quarterly Revenue Growth (1.00) | Return On Assets (0.72) | Return On Equity (1.29) |
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.